Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size, Status and Forecast 2020-2026

August 2020 | 90 pages | ID: G5DE94139ACDEN
QYResearch

Abstracts

Age-relatedMacularDegeneration (ARMD) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Age-relatedMacularDegeneration (ARMD) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study

• Roche
• Regeneron Pharmaceuticals
• Bayer
• Santen Oy
• Kanghong Pharmaceuticals
• Novartis
• Eli Lilly and Company
• TRACON Pharmaceuticals
• Pfizer
• GSK
• BIOCAD

Market segment by Type, the product can be split into

• Anti VEGF Drugs
• Photosensitive Drugs
• Others

Market segment by Application, split into

• Exudative ARMD
• Atrophy ARMD

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Age-relatedMacularDegeneration (ARMD) Drugs Revenue
1.4 Market by Type
  1.4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Anti VEGF Drugs
  1.4.3 Photosensitive Drugs
  1.4.4 Others
1.5 Market by Application
  1.5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application: 2020 VS 2026
  1.5.2 Exudative ARMD
  1.5.3 Atrophy ARMD
1.6 Study Objectives
1.7 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Perspective (2015-2026)
2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Growth Trends by Regions
  2.2.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Share by Regions (2015-2020)
  2.2.3 Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Age-relatedMacularDegeneration (ARMD) Drugs Market Growth Strategy
  2.3.6 Primary Interviews with Key Age-relatedMacularDegeneration (ARMD) Drugs Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Market Size
  3.1.1 Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Revenue (2015-2020)
  3.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Players (2015-2020)
  3.1.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio
  3.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2019
3.3 Age-relatedMacularDegeneration (ARMD) Drugs Key Players Head office and Area Served
3.4 Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
3.5 Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 MARKET SIZE BY TYPE (2015-2026)

4.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Historic Market Size by Type (2015-2020)
4.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Type (2021-2026)

5 MARKET SIZE BY APPLICATION (2015-2026)

5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)
5.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
6.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in North America (2019-2020)
6.3 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
6.4 North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
7.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in Europe (2019-2020)
7.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
7.4 Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

8 CHINA

8.1 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
8.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in China (2019-2020)
8.3 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
8.4 China Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
9.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in Japan (2019-2020)
9.3 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
9.4 Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
10.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

11 INDIA

11.1 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
11.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in India (2019-2020)
11.3 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
11.4 India Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size (2015-2020)
12.2 Age-relatedMacularDegeneration (ARMD) Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020)
12.4 Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020)

13KEY PLAYERS PROFILES

13.1 Roche
  13.1.1 Roche Company Details
  13.1.2 Roche Business Overview
  13.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.1.4 Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020))
  13.1.5 Roche Recent Development
13.2 Regeneron Pharmaceuticals
  13.2.1 Regeneron Pharmaceuticals Company Details
  13.2.2 Regeneron Pharmaceuticals Business Overview
  13.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.2.4 Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  13.2.5 Regeneron Pharmaceuticals Recent Development
13.3 Bayer
  13.3.1 Bayer Company Details
  13.3.2 Bayer Business Overview
  13.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.3.4 Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  13.3.5 Bayer Recent Development
13.4 Santen Oy
  13.4.1 Santen Oy Company Details
  13.4.2 Santen Oy Business Overview
  13.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.4.4 Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  13.4.5 Santen Oy Recent Development
13.5 Kanghong Pharmaceuticals
  13.5.1 Kanghong Pharmaceuticals Company Details
  13.5.2 Kanghong Pharmaceuticals Business Overview
  13.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.5.4 Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  13.5.5 Kanghong Pharmaceuticals Recent Development
13.6 Novartis
  13.6.1 Novartis Company Details
  13.6.2 Novartis Business Overview
  13.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.6.4 Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  13.6.5 Novartis Recent Development
13.7 Eli Lilly and Company
  13.7.1 Eli Lilly and Company Company Details
  13.7.2 Eli Lilly and Company Business Overview
  13.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.7.4 Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  13.7.5 Eli Lilly and Company Recent Development
13.8 TRACON Pharmaceuticals
  13.8.1 TRACON Pharmaceuticals Company Details
  13.8.2 TRACON Pharmaceuticals Business Overview
  13.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.8.4 TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  13.8.5 TRACON Pharmaceuticals Recent Development
13.9 Pfizer
  13.9.1 Pfizer Company Details
  13.9.2 Pfizer Business Overview
  13.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.9.4 Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  13.9.5 Pfizer Recent Development
13.10 GSK
  13.10.1 GSK Company Details
  13.10.2 GSK Business Overview
  13.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  13.10.4 GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  13.10.5 GSK Recent Development
13.11 BIOCAD
  10.11.1 BIOCAD Company Details
  10.11.2 BIOCAD Business Overview
  10.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Introduction
  10.11.4 BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020)
  10.11.5 BIOCAD Recent Development

14ANALYST'S VIEWPOINTS/CONCLUSIONS

15APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Age-relatedMacularDegeneration (ARMD) Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Age-relatedMacularDegeneration (ARMD) Drugs Revenue
Table 3. Ranking of Global Top Age-relatedMacularDegeneration (ARMD) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Anti VEGF Drugs
Table 6. Key Players of Photosensitive Drugs
Table 7. Key Players of Others
Table 8. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Regions (2015-2020)
Table 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Age-relatedMacularDegeneration (ARMD) Drugs Market Growth Strategy
Table 18. Main Points Interviewed from Key Age-relatedMacularDegeneration (ARMD) Drugs Players
Table 19. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Players (2015-2020) (Million US$)
Table 20. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Players (2015-2020)
Table 21. Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2019)
Table 22. Global Age-relatedMacularDegeneration (ARMD) Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Age-relatedMacularDegeneration (ARMD) Drugs Product Solution and Service
Table 25. Date of Enter into Age-relatedMacularDegeneration (ARMD) Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020) (Million US$)
Table 28. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Type (2015-2020)
Table 29. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Type (2021-2026)
Table 30. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Application (2015-2020)
Table 31. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020) (Million US$)
Table 32. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Share by Application (2021-2026)
Table 33. North America Key Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Age-relatedMacularDegeneration (ARMD) Drugs Market Share (2019-2020)
Table 35. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020) (Million US$)
Table 36. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2015-2020)
Table 37. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020) (Million US$)
Table 38. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2015-2020)
Table 39. Europe Key Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Age-relatedMacularDegeneration (ARMD) Drugs Market Share (2019-2020)
Table 41. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2015-2020)
Table 43. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2015-2020)
Table 45. China Key Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue (2019-2020) (Million US$)
Table 46. China Key Players Age-relatedMacularDegeneration (ARMD) Drugs Market Share (2019-2020)
Table 47. China Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020) (Million US$)
Table 48. China Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2015-2020)
Table 49. China Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020) (Million US$)
Table 50. China Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2015-2020)
Table 51. Japan Key Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Age-relatedMacularDegeneration (ARMD) Drugs Market Share (2019-2020)
Table 53. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2015-2020)
Table 55. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Age-relatedMacularDegeneration (ARMD) Drugs Market Share (2019-2020)
Table 59. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2015-2020)
Table 61. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2015-2020)
Table 63. India Key Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue (2019-2020) (Million US$)
Table 64. India Key Players Age-relatedMacularDegeneration (ARMD) Drugs Market Share (2019-2020)
Table 65. India Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020) (Million US$)
Table 66. India Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2015-2020)
Table 67. India Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020) (Million US$)
Table 68. India Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Age-relatedMacularDegeneration (ARMD) Drugs Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Age-relatedMacularDegeneration (ARMD) Drugs Market Share (2019-2020)
Table 71. Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type (2015-2020)
Table 73. Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application (2015-2020)
Table 75. Roche Company Details
Table 76. Roche Business Overview
Table 77. Roche Product
Table 78. Roche Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 79. Roche Recent Development
Table 80. Regeneron Pharmaceuticals Company Details
Table 81. Regeneron Pharmaceuticals Business Overview
Table 82. Regeneron Pharmaceuticals Product
Table 83. Regeneron Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 84. Regeneron Pharmaceuticals Recent Development
Table 85. Bayer Company Details
Table 86. Bayer Business Overview
Table 87. Bayer Product
Table 88. Bayer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 89. Bayer Recent Development
Table 90. Santen Oy Company Details
Table 91. Santen Oy Business Overview
Table 92. Santen Oy Product
Table 93. Santen Oy Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 94. Santen Oy Recent Development
Table 95. Kanghong Pharmaceuticals Company Details
Table 96. Kanghong Pharmaceuticals Business Overview
Table 97. Kanghong Pharmaceuticals Product
Table 98. Kanghong Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 99. Kanghong Pharmaceuticals Recent Development
Table 100. Novartis Company Details
Table 101. Novartis Business Overview
Table 102. Novartis Product
Table 103. Novartis Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 104. Novartis Recent Development
Table 105. Eli Lilly and Company Company Details
Table 106. Eli Lilly and Company Business Overview
Table 107. Eli Lilly and Company Product
Table 108. Eli Lilly and Company Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 109. Eli Lilly and Company Recent Development
Table 110. TRACON Pharmaceuticals Business Overview
Table 111. TRACON Pharmaceuticals Product
Table 112. TRACON Pharmaceuticals Company Details
Table 113. TRACON Pharmaceuticals Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 114. TRACON Pharmaceuticals Recent Development
Table 115. Pfizer Company Details
Table 116. Pfizer Business Overview
Table 117. Pfizer Product
Table 118. Pfizer Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 119. Pfizer Recent Development
Table 120. GSK Company Details
Table 121. GSK Business Overview
Table 122. GSK Product
Table 123. GSK Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 124. GSK Recent Development
Table 125. BIOCAD Company Details
Table 126. BIOCAD Business Overview
Table 127. BIOCAD Product
Table 128. BIOCAD Revenue in Age-relatedMacularDegeneration (ARMD) Drugs Business (2015-2020) (Million US$)
Table 129. BIOCAD Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Type: 2020 VS 2026
Figure 2. Anti VEGF Drugs Features
Figure 3. Photosensitive Drugs Features
Figure 4. Others Features
Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Application: 2020 VS 2026
Figure 6. Exudative ARMD Case Studies
Figure 7. Atrophy ARMD Case Studies
Figure 8. Age-relatedMacularDegeneration (ARMD) Drugs Report Years Considered
Figure 9. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Regions: 2020 VS 2026
Figure 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Players in 2019
Figure 14. Global Top Age-relatedMacularDegeneration (ARMD) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2019
Figure 16. North America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Age-relatedMacularDegeneration (ARMD) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed